First approved CD38-targeting monoclonal antibody for multiple myeloma

See which of your patients are suitable for DARZALEX®

It seems your browser is blocking 3rd party cookies which are required to display videos. To resolve this issue, please update your cookie settings to allow these 3rd party cookies.
Manage cookie settings
Prof. van de Donk discusses the multiple mechanisms of action of DARZALEX®

In this video, Prof. Niels van de Donk of VU University Medical Center, Amsterdam, briefly discusses the multiple mechanisms of action of DARZALEX® and how the drug promotes myeloma and immunosuppressor cell death, leading to durable anti-tumour responses

It seems your browser is blocking 3rd party cookies which are required to display videos. To resolve this issue, please update your cookie settings to allow these 3rd party cookies.
Manage cookie settings
A powerful mechanism of action

View an animation that demonstrates the multifaceted mode of action of DARZALEX® – the first approved CD38-targeting monoclonal antibody for MM

MM: multiple myeloma

Titular da Autorização de Introdução no Mercado: Janssen-Cilag International NV, Turnhoutseweg 30, B-2340 Beerse, Bélgica.
Para mais informações deverá contactar o Representante do Titular da Autorização de Introdução no Mercado: Janssen-Cilag Farmacêutica, Lda.

Medicamento de receita médica restrita, de utilização reservada a certos meios especializados.

Antes de prescrever consulte o RCM completo.

RCM de Darzalex®, veja aqui